Rheumatoid Arthritis in Adults: A Review.

Adding biological DMARDs or JAK inhibitors to first-line methotrexate therapy increases remission or low disease activity rates to approximately 80% in adults with rheumatoid arthritis.

• Why it matters: Rheumatoid arthritis can cause irreversible joint destruction and disability, making early and effective treatment crucial for improving patient outcomes and preventing long-term damage.
• What they did: The review discusses treatment strategies, highlighting that initial therapy with methotrexate, possibly combined with glucocorticoids, achieves remission in about 40% of newly diagnosed patients within 6 months, and that adding biological DMARDs or JAK inhibitors raises remission rates to around 80%.
• The result: This suggests that incorporating biological agents or JAK inhibitors after first-line treatment failure significantly enhances the likelihood of remission, supporting a stepwise approach to managing rheumatoid arthritis.